The FDA Canceled a Meeting. A Biotech Company Died.
A small biotech developing a promising liver disease treatment was killed not by bad science or a failed trial, but by a single FDA meeting cancellation. Kezar Life Sciences' collapse reveals how regulatory delays are becoming an existential threat to the companies driving biomedical innovation.
Imagine you've spent years building a restaurant. You've hired the staff, signed the lease, perfected the menu. All you need is one final inspection to open the doors. Then the inspector cancels. No explanation, no reschedule. You wait. Your savings drain. Your staff quits. Four months later, the inspector finally shows up, but by then, you've already lost everything.
That's roughly what happened to Kezar Life Sciences.
A Meeting That Never Happened
Kezar was a small biotech company developing a treatment for autoimmune hepatitis, a rare liver disease with limited competition and real unmet need. The company had about 60 employees and a drug that looked promising enough to attract investor interest. But like most small biotechs, Kezar ran on fumes. Its cash runway (the amount of time a company can operate before the money runs out) was measured in months, not years.
In October 2025, Kezar had a critical meeting scheduled with the FDA. The goal: secure a special protocol assessment, which is essentially the FDA's stamp of approval on how you plan to run your clinical trial. Think of it as getting the exam questions before the test. It doesn't guarantee you'll pass, but it tells you exactly what to study.
Then the FDA canceled. No reason given. No new date offered.
Four Months Is a Lifetime When You're Broke
For Pfizer or Johnson & Johnson, a four-month delay is a scheduling inconvenience. For a company like Kezar, it was a death sentence.
Small biotechs typically carry 12 to 18 months of cash. Every week without regulatory clarity is a week where investors get nervous, funding conversations stall, and the burn rate keeps ticking. Without the FDA meeting, Kezar couldn't tell investors what their trial would look like. And without that information, investors wouldn't write checks.
The meeting finally happened in February 2026. By then, the damage was done. Investors had pulled back. Kezar laid off most of its roughly 60 employees, auctioned off lab equipment, and began winding down operations. The company was eventually sold to Aurinia Pharmaceuticals, which may continue developing the drug, though there's no guaranteed timeline.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
CEO Chris Kirk pointed the finger squarely at the FDA, citing volatility, staff departures, and inconsistent decision-making that disproportionately crushes smaller firms.
The FDA Is Losing People, Fast
Kezar's story doesn't exist in a vacuum. The FDA is going through its own slow-motion crisis.
The agency's workforce has shrunk by roughly 20%, or about 3,500 positions, through a combination of layoffs, retirements, buyouts, and DOGE-directed cuts. The FY 2026 budget came in at $6.8 billion, a 3.9% decrease from the prior year, with nearly 1,940 full-time positions eliminated on paper.
Those aren't just numbers. They're the people who read your drug application, run your pre-trial meeting, and decide whether your molecule gets a shot at helping patients. When those people leave, the institutional knowledge walks out the door with them.
Peter Stein, the former Director of the Office of New Drugs, was forced out. Leadership vacuums formed. Meetings got postponed. First-in-class drugs, AI-driven development programs, and ultra-rare disease treatments all felt the squeeze.
The FDA managed to approve 46 novel drugs in 2025, and officially met or exceeded 8 of 10 PDUFA performance goals (the statutory deadlines Congress sets for drug reviews). On the surface, the system held. But dig a little deeper and cracks appear: the on-time approval rate dipped to 78% in the second half of 2025, compared to a historical average of 85 to 90%. That gap represents real companies, real patients, and real consequences.
Big Pharma Shrugs; Small Biotechs Suffocate
This is the part that should make you angry, or at least concerned.
Large pharmaceutical companies have the resources to weather regulatory storms. They carry years of cash, maintain armies of regulatory affairs specialists, and run dozens of programs simultaneously. A four-month delay on one program is annoying; it's not existential.
Small biotechs are a different animal entirely. Many are built around a single drug candidate. Their entire business plan depends on hitting regulatory milestones on time, because those milestones unlock the next round of funding. It's like a relay race where each baton pass has to happen on schedule, or the whole team collapses.
An RBC Capital Markets survey found that nearly half of investors identified the FDA's unpredictable regulatory climate as the biotech industry's biggest issue in early 2026. When the people writing the checks are that worried, capital dries up fast.
Kezar isn't an isolated case, either. Aldeyra Therapeutics saw its PDUFA target action date for a dry eye treatment pushed from December 2025 to March 2026 after the FDA requested a report on a previously excluded failed trial, despite prior written agreement to the contrary.
The pattern is consistent: small companies get blindsided by delays they can't absorb.
More Than 200 CEOs Are Sounding the Alarm
The frustration has boiled over into collective action. Over 200 biotech CEOs have signed letters urging Congressional intervention, citing delayed approvals and eroding investor confidence. The National Security Commission on Emerging Biotechnology went further on April 7, 2026, criticizing the FDA's processes for causing delays that "stall review and stifle industry growth." The commission proposed reforms, including a new Clinical Trial Notification Pathway that would bypass the traditional (and often burdensome) Investigational New Drug submission process.
Meanwhile, the FDA has launched some streamlining efforts: a "national priority" voucher program that can cut review times to weeks for qualifying drugs, expanded evidence pathways for rare diseases, and a proposal to require only one Phase 3 trial instead of two for certain approvals. These are steps in the right direction, but they don't help the company that already closed its doors.
Why This Matters Beyond One Company
It's tempting to read Kezar's story as a cautionary tale about one unlucky startup. But the implications are much broader.
Small biotechs are where a huge share of biomedical innovation happens. They take the early, risky bets on novel science that big pharma typically won't touch until the data looks promising. Kill the small biotechs, and you choke the pipeline of future medicines before they ever reach a patient.
Investors are already adapting to the new reality, and not in a good way. Many now demand 24-plus months of cash runway and diversified asset portfolios before they'll invest. That sounds prudent until you realize it effectively shuts out the earliest-stage companies, the ones most likely to be working on breakthrough science with the thinnest margins for error.
The Bottom Line
Kezar Life Sciences didn't fail because its science was bad. It didn't fail because the market didn't want its drug. It failed because a meeting got canceled and nobody rescheduled it for four months.
That should terrify anyone who cares about where the next generation of medicines comes from. The FDA has an impossible job: protect public safety while moving fast enough to keep innovation alive. Nobody envies that balancing act. But when a single canceled meeting can kill a company, the system isn't just slow; it's broken in a way that disproportionately punishes the smallest, most innovative players in the game.
The fix isn't simple, but the diagnosis is clear. The FDA needs stable funding, consistent staffing, and predictable timelines. Not because biotech CEOs deserve sympathy (though some do), but because patients are waiting for drugs that may never arrive.
Aurinia Pharmaceuticals picked up what's left of Kezar. Maybe the drug will survive. But the company, the team, and the years of work? Those are gone. All because of four months.
Deals & M&A
4 min read
Two Pharma Giants Went Shopping on the Same Day. Biotech Went Ballistic.
Eli Lilly and Biogen dropped nearly $14 billion in acquisitions on the same day, sending the biotech index soaring 7%. It might be just the beginning of a record-breaking M&A year.
